Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2018 | FLT3 inhibitors in the treatment of AML

Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, describes which FLT3 inhibitors his group uses to treat different subsets of patients with acute myeloid leukemia (AML ). This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.